Skin changes on continued imatinib therapy in patients with Ph+ CML

被引：0
|
作者：
Saikia, Tapan [1 ]
Hazarika, Nandim [1 ]
Dhabhar, Boman [1 ]
机构：
[1] Prince Aly Khan Hosp, Bombay, Maharashtra, India
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.2963.2963
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2963
引用
收藏
页码：870A / 870A
页数：1
相关论文
共 50 条
  • [1] Skin changes on continued imatinib therapy in patients with Ph CML
    Saikia, Tapan K.
    Hazarika, N.
    Dhabhar, B. N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 245 - 245
  • [2] Aurora kinase inhibitors in the treatment of CML and Ph+ all patients resistant to imatinib
    Papayannidis, C.
    Iacobucci, I.
    Paolini, S.
    Piccaluga, P. P.
    De, Rosa F.
    Lama, B.
    Laterza, C.
    Giannoulia, P.
    Verlicchi, L.
    Chiavaroli, F.
    Ottaviani, E.
    Baccarani, M.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 45 - 46
  • [3] Influence of antecedent Glivec® therapy (imatinib mesylate) on allogeneic stem cell transplantation outcome in CML Ph+ and ALL Ph+ patients -: single-centre experience
    Holowiecki, J
    Kruzel, T
    Wojnar, J
    Krawczyk-Kulis, M
    Wylezol, I
    BONE MARROW TRANSPLANTATION, 2004, 33 : S138 - S138
  • [4] Allogeneic stem cell transplantation from unrelated and related donors is effective in CML Ph+ and ALL Ph+ patients pretreated with imatinib.
    Holowiecki, J
    Kruzel, T
    Wojnar, J
    Krawczyk, M
    Skotnicki, A
    Holowiecka, B
    Kuliczkowski, K
    Hellman, A
    Wylezal, I
    Kata, D
    BLOOD, 2003, 102 (11) : 436B - 436B
  • [5] A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL
    Arinobu Tojo
    Kensuke Usuki
    Akio Urabe
    Yasuhiro Maeda
    Yukio Kobayashi
    Itsuro Jinnai
    Kazuma Ohyashiki
    Miki Nishimura
    Tatsuya Kawaguchi
    Hideo Tanaka
    Koichi Miyamura
    Yasushi Miyazaki
    Timothy Hughes
    Susan Branford
    Shinichiro Okamoto
    Jun Ishikawa
    Masaya Okada
    Noriko Usui
    Hiromi Tanii
    Taro Amagasaki
    Hiroko Natori
    Tomoki Naoe
    International Journal of Hematology, 2009, 89 : 679 - 688
  • [6] Acquired genomic copy number changes in CML patients with the Philadelphia chromosome (Ph+)
    Lu, Xianglan
    Wang, Xianfu
    Kim, Yougmi
    Zhang, Rui
    Li, Shibo
    Lee, Ji-Yun
    CANCER GENETICS, 2012, 205 (10) : 513 - 518
  • [7] THE BASELINE HISTORY OF RESISTANCE AND INTOLERANCE IN PH+ CML PATIENTS FAILING TKI THERAPY
    Ayala, M.
    Ayala, A.
    Giuliani, A.
    Lopez, L.
    Lobo, D. De Castro
    Mendes, L.
    Woodman, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 541 - 541
  • [8] Hematology: Nilotinib as first-line therapy for Ph+ CML
    Hutchinson L.
    Nature Reviews Clinical Oncology, 2010, 7 (2) : 67 - 67
  • [9] MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure
    M Agrawal
    B Hanfstein
    P Erben
    D Wolf
    T Ernst
    A Fabarius
    S Saussele
    D Purkayastha
    R C Woodman
    W-K Hofmann
    R Hehlmann
    A Hochhaus
    M C Müller
    Leukemia, 2014, 28 : 1478 - 1485
  • [10] Ponatinib superior to imatinib in Ph+ ALL
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (07) : 483 - 483
12345